GlassScriptPhysician profile
Hope Allen
NPI 1497322838
$6,325.58
in general payments reported to CMS, 2019-2025
23 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $821 · 2023: $1,748 · 2024: $2,002 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,197 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,197.39 |
| Education | $307.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,121.46 | 2022-2025 | Tremfya |
| Abbvie INC. | $760.33 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $609.53 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $565.09 | 2022-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $513.46 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $513.14 | 2022-2025 | |
| Ucb, INC. | $358.61 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $299.04 | 2023-2024 | Vtama |
| Leo Pharma INC. | $288.94 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $255.91 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $191.24 | 2022-2025 | |
| Amgen INC. | $178.52 | 2022-2025 | Otezla, Otezla |
| Journey Medical Corporation | $129.16 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Incyte Corporation | $95.79 | 2022-2025 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $81.91 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.66 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $43.38 | 2022-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $40.54 | 2023 | |
| Verrica Pharmaceuticals INC. | $37.35 | 2024 | Ycanth |
| Pfizer INC. | $36.01 | 2023-2024 | |
| Botanix Sb INC | $17.70 | 2025 | Sofdra |
| Almirall LLC | $14.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.